Major PBM Looks to Stem Gilead Sciences' (GILD) Hepatitis C Profits

Merck (MRK) Over-Hyped in Hep C, Says Wells Fargo (GILD) (ABBV)

Wells Fargo analyst Brian Abrahams said Merck (NYSE: MRK) may be over-hyped as a hepC competitor to Gilead Sciences (NASDAQ: GILD).

"We are attending the EASL conference in London UK, where Merck has just pressreleased additional data from... More

Maxim Remains Positive on Gilead (GILD); Sovaldi is Compelling HCV Treatment from Cost-Benefit Perspective

Gilead Sciences (Nasdq: GILD) is up early Wednesday following positive commentary out of Maxim Group. The firm has Gilead at Buy with a price target of $101.

Analyst Jason Kolbert, commented, Gilead was pilloried again yesterday for developing a drug (Sovaldi) with the highest efficacy and fewest side effects, but at a high (but not the highest) price for a new... More

Gilead Sciences, Inc. (GILD) Receives FDA Priority Review Date for Ledipasvir + Sofosbuvir NDA as HCV Treatment

Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the companys New Drug Application (NDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults. Gilead filed the NDA for LDV/SOF on February 10, 2014, and the... More

Blood-Bath in Nasdaq Stocks

Stocks are under heavy mid-day pressure Friday, led by the blood-letting in high-growth, high-multiple momentum names that litter the Nasdaq. The Nasdaq is down 88 points, or 2%, while the Dow and S&P 400 are lower but down just 0.3% and 0.5%, respectively.

The selling that started in the biotech sector a... More

Gilead Sciences, Inc. (GILD) Sovaldi TRx +4%, NRx +4% - ISI

According to a tweet from ISI's Mark Schoenebaum, Gilead Sciences, Inc. (NASDAQ: GILD) Sovaldi TRx +4%, NRx +4%.

Schoenebaum included the following chart showing the Sovaldi launch trajectories versus Incivek.